Full-Time

Head of Market Access

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$260k - $301kAnnually

Senior, Expert

San Carlos, CA, USA

In-office presence required at least 3 days per week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Develop RevMed’s market access strategy and tactics to ensure successful initial product launches and maximization of lifecycle value.
  • Design and lead execution of access, reimbursement & pricing plans.
  • Stay abreast of market dynamics and trends; incorporate appropriately into strategy and planning.
  • Provide strategic leadership and direction for payer access, coverage, reimbursement, patient support services, pricing and distribution, list and net pricing, and contracting across all payer types.
  • Design and drive the strategic plan for market access capabilities within the US (and globally as needed) including strategic account management, patient access programs, trade and distribution, contracting, and health economics and pricing.
  • Develop US pricing recommendations to ensure alignment as it relates to contracting, rebating, price adjustments, best price, and other related elements.
  • Work collaboratively to recommend and execute a US managed care strategy for payer and key channels, including commercial insurers, Pharmacy Benefit Managers (PBMs), Integrated Health Networks (IHN), State Medicaid, Medicare, and Federal VA/DoD channels.
  • Proactively meet with senior leadership at key U.S. payers to identify opportunities for broader collaboration and partnership, including both regional and national health plans.
  • Collaborate with Marketing in the development of the product value proposition and other resources for payer account managers, and pull-through communications and resources for the US field team(s).
  • Oversee the design and execution of the patient support services hub.
  • Build and lead a high-functioning Market Access team and infrastructure to ensure optimal access solutions for patients and providers, including the appropriate field-based customer team to ensure optimal access.
  • In partnership with Medical Affairs and Clinical Development, ensure clinical research incorporates HEOR needs, and be responsible for the health economic and broader value assessment. Oversee the development of budget impact and cost-effectiveness models.
  • Collaboration: Strong collaboration skills, both within commercial teams and cross-functional teams including R&D, marketing, sales, manufacturing, and medical affairs.
  • Deep understanding of and compliance with the OIG and FDA regulations.
  • In the office at least 3 days per week with the ability to travel as needed.
  • BS/BA degree; master’s degree or higher preferred.
  • Minimum of fifteen (15) years of biopharmaceutical market access experience, including payer, reimbursement, pricing & contracting, field team leadership, and established relationships with several key national and regional payers.
  • Broad commercial experience including oncology product launches.
  • Strong understanding of healthcare policy, payer dynamics, healthcare system, and regulatory landscape.
  • Proven leadership experience building from the ground up and leading high-performing teams.
  • Excellent communication and negotiation skills.
Responsibilities
  • Lead and mentor a high-performing market access team, providing guidance and support in executing strategic initiatives.
  • Foster a collaborative and results-oriented culture within the market access function.
  • The ability to direct, lead, and manage remote teams.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?